Alessandra Hermógenes Gomes Tobias
Research Subjects
Alessandra Hermógenes Gomes Tobias has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Daniela Ushizima
Applied Math and Computational Research Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
2 shared publications - Fatima Nelsizeuma Sombra Medeiros
Departamento de Engenharia de Teleinformática, Universidade Federal do Ceará (UFC), Fortaleza 60455-970, Brazil
2 shared publications A. C. Vitalino
Post-Graduate Program in Pharmaceutical Sciences, School of Pharmacy, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil
1 shared publication- Agnaldo Lopes da Silva Filho
Universidade Federal de Minas Gerais Belo Horizonte MG Brazil Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
1 shared publication - Aline Ferreira Maciel de Oliveira
Laboratory of Cellular and Molecular Genetics, Department of Genetics, Ecology and Evolution, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil
1 shared publication Andrea G. C. Bianchi
Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil
1 shared publication
Latest Publications
- Open Access
- 19 November 2026
- Published by MDPI AG in Venereology
- Vol. 5 (4) , 25
Bacterial Vaginosis and Dysbiosis: Insights into Pathogenic Infections and Trichomoniasis
Background/Objectives: Bacterial vaginosis (BV) is the leading cause of vaginal dysbiosis and remains a public health concern due to its high prevalence, recurrence, and association with adverse reproductive and infectious outcomes. Advances in next-generation sequencing (NGS) and microbiome characterization have redefined BV by revealing microbial composition profiles known as Community State Types (CSTs). Once regarded primarily as a polymicrobial infection, BV is now recognized as a multifactorial ecological disorder marked by microbiome instability, Lactobacillus depletion, anaerobic overgrowth, host–microbe interactions, and clinical heterogeneity. Methods: This narrative review critically analyzes recent evidence on vaginal microbial ecology, the transition from eubiosis to dysbiosis, and the mechanisms underlying BV development, persistence, and recurrence. This review focuses on interactions between BV-associated microorganisms and Trichomonas vaginalis, including microbial persistence, immune modulation, and susceptibility to Sexually Transmitted Infections (STIs). Results: BV involves ecological, metabolic, and immunological changes, including polymicrobial biofilm formation, alterations in the mucosal metabolome, and impaired resistance to colonization by other microorganisms. These changes may facilitate microbial persistence, recurrence, and T. vaginalis persistence. This is reflected in the association between BV and an increased risk of STIs, although the cause has not yet been fully established. Microbial resistance and recurrence underscore the need for new interventions, while probiotics, live biotherapeutic products, vaginal microbiota transplantation (VMT), targeted therapies, and vaccines have shown promising results. Conclusions: Integrating microbiological, immunological, and clinical evidence, this review provides a framework for BV pathophysiology and its association with T. vaginalis, supporting personalized therapeutic and prophylactic strategies.
- 19 November 2026
- Published by MDPI AG in Venereology
- Vol. 5 (4) , 25
Open AccessBacterial Vaginosis and Dysbiosis: Insights into Pathogenic Infections and Trichomoniasis
Background/Objectives: Bacterial vaginosis (BV) is the leading cause of vaginal dysbiosis and remains a public health concern due to its high prevalence, recurrence, and association with adverse reproductive and infectious outcomes. Advances in next-generation sequencing (NGS) and microbiome characterization have redefined BV by revealing microbial composition profiles known as Community State Types (CSTs). Once regarded primarily as a polymicrobial infection, BV is now recognized as a multifactorial ecological disorder marked by microbiome instability, Lactobacillus depletion, anaerobic overgrowth, host–microbe interactions, and clinical heterogeneity. Methods: This narrative review critically analyzes recent evidence on vaginal microbial ecology, the transition from eubiosis to dysbiosis, and the mechanisms underlying BV development, persistence, and recurrence. This review focuses on interactions between BV-associated microorganisms and Trichomonas vaginalis, including microbial persistence, immune modulation, and susceptibility to Sexually Transmitted Infections (STIs). Results: BV involves ecological, metabolic, and immunological changes, including polymicrobial biofilm formation, alterations in the mucosal metabolome, and impaired resistance to colonization by other microorganisms. These changes may facilitate microbial persistence, recurrence, and T. vaginalis persistence. This is reflected in the association between BV and an increased risk of STIs, although the cause has not yet been fully established. Microbial resistance and recurrence underscore the need for new interventions, while probiotics, live biotherapeutic products, vaginal microbiota transplantation (VMT), targeted therapies, and vaccines have shown promising results. Conclusions: Integrating microbiological, immunological, and clinical evidence, this review provides a framework for BV pathophysiology and its association with T. vaginalis, supporting personalized therapeutic and prophylactic strategies.
- Open Access
- 23 October 2026
- Published by Instituto Mário Penna in Mário Penna Journal
- Vol. 3 (1) , 29-32
AVALIAÇÃO CLÍNICA E CITOPATOLÓGICA DARADIOFREQUÊNCIA FRACIONADA MICROABLATIVA EMMULHERES SUBMETIDAS À QUIMIORRADIOTERAPIA PORCÂNCER DE COLO DE ÚTERO
Introdução: O Câncer de colo uterino (CCU) é o terceiro câncer mais comum entre as mulheres no Brasil e a quarta causa de morte. O tratamento do CCU baseia-se em sessões de quimiorradioterapia antes e/ou depois da intervenção cirúrgica. As altas doses de radiação podem causar atrofia vulvovaginal por hipoestrogenismo e lesão celular direta, desencadeando ardor, irritação, falta de lubrificação, urgência, polaciúria, disúria, propensão a infecções urinárias, e sobretudo, ressecamento vulvovaginal e dispareunia. O tratamento desses sintomas requer uma abordagem multidisciplinar. A radiofrequência fracionada microablativa (RFFMA) surge como tecnologia para reabilitação tecidual e funcional, podendo integrar estratégias de inovação assistencial. Objetivo: Avaliar o efeito terapêutico da RFFMA na melhora da atrofia vaginal e saúde sexual feminina. Delineamento e Métodos: Estudo clínico prospectivo recrutando pacientes com CCU atendidas no Instituto Mario Penna. As participantes foram randomizadas em dois grupos de tratamento: (i) estrogênio tópico vaginal e (ii) RFFMA. Foram realizados três ciclos de intervenção, com avaliações nos tempos D0, D1, D2 e D3, através de análise citopatológica e o questionário Quociente Sexual Feminino (QS-F). A análise estatística foi realizada no software GraphPad Prism (p < 0,05). Resultados: Um total de 105 pacientes foram recrutadas, com idade entre 28-78 anos, 89,7% foram diagnosticadas com carcinoma de células escamosas. Apenas 20 pacientes apresentaram condições clínicas para inclusão no projeto e aceitaram participar, assinando o TCLE. Destas, 10 foram randomizadas para o grupo do estrogênio tópico vaginal e 10 para RFFMA. Três participantes interromperam a participação por questões pessoais, duas do grupo da RFFMA e uma do estrogênio tópico vaginal. A análise do QS-F mostra que a maioria das pacientes relatam impacto positivo sobre os parâmetros de qualidade de vida sexual após as intervenções, em ambos os grupos. Contudo, nenhuma diferença estatisticamente significativa foi identificada. Cinco pacientes finalizaram as intervenções com RFFMA e mostraram boa tolerância ao procedimento. Os esfregaços citológicos mostraram, de maneira geral, melhora do trofismo celular e redução do infiltrado inflamatório. Conclusão: Esses resultados apontam a possibilidade da RFFMA como alternativa terapêutica inovadora e segura, capaz de contribuir para a reabilitação funcional e sexual de mulheres após o tratamento oncológico.
- 23 October 2026
- Published by Instituto Mário Penna in Mário Penna Journal
- Vol. 3 (1) , 29-32
Open AccessAVALIAÇÃO CLÍNICA E CITOPATOLÓGICA DARADIOFREQUÊNCIA FRACIONADA MICROABLATIVA EMMULHERES SUBMETIDAS À QUIMIORRADIOTERAPIA PORCÂNCER DE COLO DE ÚTERO
Introdução: O Câncer de colo uterino (CCU) é o terceiro câncer mais comum entre as mulheres no Brasil e a quarta causa de morte. O tratamento do CCU baseia-se em sessões de quimiorradioterapia antes e/ou depois da intervenção cirúrgica. As altas doses de radiação podem causar atrofia vulvovaginal por hipoestrogenismo e lesão celular direta, desencadeando ardor, irritação, falta de lubrificação, urgência, polaciúria, disúria, propensão a infecções urinárias, e sobretudo, ressecamento vulvovaginal e dispareunia. O tratamento desses sintomas requer uma abordagem multidisciplinar. A radiofrequência fracionada microablativa (RFFMA) surge como tecnologia para reabilitação tecidual e funcional, podendo integrar estratégias de inovação assistencial. Objetivo: Avaliar o efeito terapêutico da RFFMA na melhora da atrofia vaginal e saúde sexual feminina. Delineamento e Métodos: Estudo clínico prospectivo recrutando pacientes com CCU atendidas no Instituto Mario Penna. As participantes foram randomizadas em dois grupos de tratamento: (i) estrogênio tópico vaginal e (ii) RFFMA. Foram realizados três ciclos de intervenção, com avaliações nos tempos D0, D1, D2 e D3, através de análise citopatológica e o questionário Quociente Sexual Feminino (QS-F). A análise estatística foi realizada no software GraphPad Prism (p < 0,05). Resultados: Um total de 105 pacientes foram recrutadas, com idade entre 28-78 anos, 89,7% foram diagnosticadas com carcinoma de células escamosas. Apenas 20 pacientes apresentaram condições clínicas para inclusão no projeto e aceitaram participar, assinando o TCLE. Destas, 10 foram randomizadas para o grupo do estrogênio tópico vaginal e 10 para RFFMA. Três participantes interromperam a participação por questões pessoais, duas do grupo da RFFMA e uma do estrogênio tópico vaginal. A análise do QS-F mostra que a maioria das pacientes relatam impacto positivo sobre os parâmetros de qualidade de vida sexual após as intervenções, em ambos os grupos. Contudo, nenhuma diferença estatisticamente significativa foi identificada. Cinco pacientes finalizaram as intervenções com RFFMA e mostraram boa tolerância ao procedimento. Os esfregaços citológicos mostraram, de maneira geral, melhora do trofismo celular e redução do infiltrado inflamatório. Conclusão: Esses resultados apontam a possibilidade da RFFMA como alternativa terapêutica inovadora e segura, capaz de contribuir para a reabilitação funcional e sexual de mulheres após o tratamento oncológico.
- Open Access
- 10 June 2021
- Published by Springer Nature in Scientific Data
- Vol. 8 (1) , 1-8
Cric searchable image database as a public platform for conventional pap smear cytology data
Amidst the current health crisis and social distancing, telemedicine has become an important part of mainstream of healthcare, and building and deploying computational tools to support screening more efficiently is an increasing medical priority. The early identification of cervical cancer precursor lesions by Pap smear test can identify candidates for subsequent treatment. However, one of the main challenges is the accuracy of the conventional method, often subject to high rates of false negative. While machine learning has been highlighted to reduce the limitations of the test, the absence of high-quality curated datasets has prevented strategies development to improve cervical cancer screening. The Center for Recognition and Inspection of Cells (CRIC) platform enables the creation of CRIC Cervix collection, currently with 400 images (1,376 × 1,020 pixels) curated from conventional Pap smears, with manual classification of 11,534 cells. This collection has the potential to advance current efforts in training and testing machine learning algorithms for the automation of tasks as part of the cytopathological analysis in the routine work of laboratories.
- 10 June 2021
- Published by Springer Nature in Scientific Data
- Vol. 8 (1) , 1-8
Open AccessCric searchable image database as a public platform for conventional pap smear cytology data
Amidst the current health crisis and social distancing, telemedicine has become an important part of mainstream of healthcare, and building and deploying computational tools to support screening more efficiently is an increasing medical priority. The early identification of cervical cancer precursor lesions by Pap smear test can identify candidates for subsequent treatment. However, one of the main challenges is the accuracy of the conventional method, often subject to high rates of false negative. While machine learning has been highlighted to reduce the limitations of the test, the absence of high-quality curated datasets has prevented strategies development to improve cervical cancer screening. The Center for Recognition and Inspection of Cells (CRIC) platform enables the creation of CRIC Cervix collection, currently with 400 images (1,376 × 1,020 pixels) curated from conventional Pap smears, with manual classification of 11,534 cells. This collection has the potential to advance current efforts in training and testing machine learning algorithms for the automation of tasks as part of the cytopathological analysis in the routine work of laboratories.
- 1 December 2019
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 182, 105053
Saliency-driven system models for cell analysis with deep learning
- 1 December 2019
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 182, 105053
Saliency-driven system models for cell analysis with deep learning
- 15 June 2018
- Published by Wiley in Cytopathology
- Vol. 29 (5) , 428-435
Performance of rapid prescreening and 100% rapid review as internal quality control methods for cervical cytopathology
Background: An objective of quality control for cervical cytopathology is reducing high rates of false‐negative results of laboratory tests. Therefore, methods to review smears such as rapid prescreening and 100% rapid review, which have shown better performance detecting false‐negative results, have been widely used. The performance of rapid prescreening and the performance of 100% rapid review as internal quality control methods for cervical cytology examinations were evaluated.Methods: For 24 months, 9318 conventional cervical cytology smears underwent rapid prescreening and routine screening. The 100% rapid review method was performed for 8244 smears classified as negative during routine screening. Any discordant results underwent detailed review to define the final diagnosis. This was considered the gold standard for evaluating the performance of rapid prescreening and 100% rapid review.Results: Routine screening showed increases of 13.3% and 11.5% in the detection of abnormal smears with rapid prescreening and 100% rapid review, respectively. The relative percentage variation showed a 38.1% increase in the diagnosis of atypical squamous cells of undetermined significance with routine screening and rapid prescreening and a 12.5% increase in the diagnosis of atypical squamous cells, cannot exclude high‐grade squamous intraepithelial lesion with both rapid prescreening and 100% rapid review. Sensitivity rates of rapid prescreening and routine screening were 48.2% and 83.2%, respectively. Sensitivity rates of rapid prescreening and 100% rapid review were 65.7% and 57.8%, respectively, for detecting false‐negative results.Conclusions: Inclusion of rapid prescreening and/or 100% rapid review improved the diagnostic sensitivity of the cervical cytology examination and reduced false‐negative results of routine screening and can provide good quality control.
- 15 June 2018
- Published by Wiley in Cytopathology
- Vol. 29 (5) , 428-435
Performance of rapid prescreening and 100% rapid review as internal quality control methods for cervical cytopathology
Background: An objective of quality control for cervical cytopathology is reducing high rates of false‐negative results of laboratory tests. Therefore, methods to review smears such as rapid prescreening and 100% rapid review, which have shown better performance detecting false‐negative results, have been widely used. The performance of rapid prescreening and the performance of 100% rapid review as internal quality control methods for cervical cytology examinations were evaluated.Methods: For 24 months, 9318 conventional cervical cytology smears underwent rapid prescreening and routine screening. The 100% rapid review method was performed for 8244 smears classified as negative during routine screening. Any discordant results underwent detailed review to define the final diagnosis. This was considered the gold standard for evaluating the performance of rapid prescreening and 100% rapid review.Results: Routine screening showed increases of 13.3% and 11.5% in the detection of abnormal smears with rapid prescreening and 100% rapid review, respectively. The relative percentage variation showed a 38.1% increase in the diagnosis of atypical squamous cells of undetermined significance with routine screening and rapid prescreening and a 12.5% increase in the diagnosis of atypical squamous cells, cannot exclude high‐grade squamous intraepithelial lesion with both rapid prescreening and 100% rapid review. Sensitivity rates of rapid prescreening and routine screening were 48.2% and 83.2%, respectively. Sensitivity rates of rapid prescreening and 100% rapid review were 65.7% and 57.8%, respectively, for detecting false‐negative results.Conclusions: Inclusion of rapid prescreening and/or 100% rapid review improved the diagnostic sensitivity of the cervical cytology examination and reduced false‐negative results of routine screening and can provide good quality control.
- Open Access
- 1 February 2016
- Published by Federação das Associações de Ginecologia e Obstetrícia in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 38 (02) , 065-070
Quality Indicators of Cervical Cytopathology Tests in the Public Service in Minas Gerais, Brazil
Objective The objective of this study is to assess the performance of cytopathology laboratories providing services to the Brazilian Unified Health System (Sistema Único de Saúde – SUS) in the State of Minas Gerais, Brazil. Methods This descriptive study uses data obtained from the Cervical Cancer Information System from January to December 2012. Three quality indicators were analyzed to assess the quality of cervical cytopathology tests: positivity index, percentage of atypical squamous cells (ASCs) in abnormal tests, and percentage of tests compatible with high-grade squamous intraepithelial lesions (HSILs). Laboratories were classified according to their production scale in tests per year ≤ 5,000; from 5,001 to 10,000; from 10,001 to 15,000; and ≥ 15,001. Based on the collection of variables and the classification of laboratories according to production scale, we created and analyzed a database using Microsoft Office Excel 97–2003. Results In the Brazilian state of Minas Gerais, 146 laboratories provided services to the SUS in 2012 by performing a total of 1,277,018 cervical cytopathology tests. Half of these laboratories had production scales ≤ 5,000 tests/year and accounted for 13.1% of all tests performed in the entire state; in turn, 13.7% of these laboratories presented production scales of > 15,001 tests/year and accounted for 49.2% of the total of tests performed in the entire state. The positivity indexes of most laboratories providing services to the SUS in 2012, regardless of production scale, were below or well below recommended limits. Of the 20 laboratories that performed more than 15,001 tests per year, only three presented percentages of tests compatible with HSILs above the lower limit recommended by the Brazilian Ministry of Health. Conclusion The majority of laboratories providing services to the SUS in Minas Gerais presented quality indicators outside the range recommended by the Brazilian Ministry of Health. Objetivo Avaliar o desempenho dos laboratórios de citopatologia prestadores de serviço para o Sistema Único de Saúde (SUS) no estado de Minas Gerais, Brasil. Métodos estudo descritivo com base nos dados obtidos do Sistema de Informação do Câncer do Colo do Útero no período de janeiro a dezembro de 2012. Para avaliação da qualidade dos exames citopatológicos do colo do útero, foram analisados três indicadores de qualidade: índice de positividade, percentual de ASC (células escamosas atípicas) entre os exames alterados e percentual de exames compatíveis com HSIL (Lesão intraepitelial escamosa de alto grau). Os laboratórios foram classificados conforme escala de produção em: ≤ 5.000; entre 5.001 e 10.000; entre 10.001 e 15.000 e ≥ 15.001. Após a coleta das variáveis e classificação dos laboratórios conforme escala de produção foi elaborado um banco de dados, o qual foi analisado por meio do programa Microsoft Office Excel 97-2003. Resultados Em 2012, no estado de Minas Gerais, 146 laboratórios prestaram serviço para o SUS realizando um total de 1.277.018 exames citopatológicos do colo do útero. Metade desses laboratórios apresentou escala de produção ≤ 5.000 exames/ano, e efetuaram 13,1% do total de exames do estado, por outro lado 13,7% dos laboratórios apresentaram escala de produção > 15.001 exames/ano e efetuaram 49,2% do total de exames do estado. O índice de positividade apresentado pela maioria dos laboratórios que prestaram serviço para o SUS no ano de 2012, independente de sua escala de produção, foi abaixo ou muito abaixo do recomendado. Dentre os 20 laboratórios que efetuaram mais de 15.001 exames por ano, somente três apresentaram o percentual de exames compatíveis com HSIL acima do recomendado pelo Ministério da Saúde. Conclusão A maioria dos laboratórios prestadores de serviço para o SUS no estado de Minas Gerais apresentou indicadores de qualidade fora dos parâmetros recomendados pelo Ministério da Saúde.
- 1 February 2016
- Published by Federação das Associações de Ginecologia e Obstetrícia in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 38 (02) , 065-070
Open AccessQuality Indicators of Cervical Cytopathology Tests in the Public Service in Minas Gerais, Brazil
Objective The objective of this study is to assess the performance of cytopathology laboratories providing services to the Brazilian Unified Health System (Sistema Único de Saúde – SUS) in the State of Minas Gerais, Brazil. Methods This descriptive study uses data obtained from the Cervical Cancer Information System from January to December 2012. Three quality indicators were analyzed to assess the quality of cervical cytopathology tests: positivity index, percentage of atypical squamous cells (ASCs) in abnormal tests, and percentage of tests compatible with high-grade squamous intraepithelial lesions (HSILs). Laboratories were classified according to their production scale in tests per year ≤ 5,000; from 5,001 to 10,000; from 10,001 to 15,000; and ≥ 15,001. Based on the collection of variables and the classification of laboratories according to production scale, we created and analyzed a database using Microsoft Office Excel 97–2003. Results In the Brazilian state of Minas Gerais, 146 laboratories provided services to the SUS in 2012 by performing a total of 1,277,018 cervical cytopathology tests. Half of these laboratories had production scales ≤ 5,000 tests/year and accounted for 13.1% of all tests performed in the entire state; in turn, 13.7% of these laboratories presented production scales of > 15,001 tests/year and accounted for 49.2% of the total of tests performed in the entire state. The positivity indexes of most laboratories providing services to the SUS in 2012, regardless of production scale, were below or well below recommended limits. Of the 20 laboratories that performed more than 15,001 tests per year, only three presented percentages of tests compatible with HSILs above the lower limit recommended by the Brazilian Ministry of Health. Conclusion The majority of laboratories providing services to the SUS in Minas Gerais presented quality indicators outside the range recommended by the Brazilian Ministry of Health. Objetivo Avaliar o desempenho dos laboratórios de citopatologia prestadores de serviço para o Sistema Único de Saúde (SUS) no estado de Minas Gerais, Brasil. Métodos estudo descritivo com base nos dados obtidos do Sistema de Informação do Câncer do Colo do Útero no período de janeiro a dezembro de 2012. Para avaliação da qualidade dos exames citopatológicos do colo do útero, foram analisados três indicadores de qualidade: índice de positividade, percentual de ASC (células escamosas atípicas) entre os exames alterados e percentual de exames compatíveis com HSIL (Lesão intraepitelial escamosa de alto grau). Os laboratórios foram classificados conforme escala de produção em: ≤ 5.000; entre 5.001 e 10.000; entre 10.001 e 15.000 e ≥ 15.001. Após a coleta das variáveis e classificação dos laboratórios conforme escala de produção foi elaborado um banco de dados, o qual foi analisado por meio do programa Microsoft Office Excel 97-2003. Resultados Em 2012, no estado de Minas Gerais, 146 laboratórios prestaram serviço para o SUS realizando um total de 1.277.018 exames citopatológicos do colo do útero. Metade desses laboratórios apresentou escala de produção ≤ 5.000 exames/ano, e efetuaram 13,1% do total de exames do estado, por outro lado 13,7% dos laboratórios apresentaram escala de produção > 15.001 exames/ano e efetuaram 49,2% do total de exames do estado. O índice de positividade apresentado pela maioria dos laboratórios que prestaram serviço para o SUS no ano de 2012, independente de sua escala de produção, foi abaixo ou muito abaixo do recomendado. Dentre os 20 laboratórios que efetuaram mais de 15.001 exames por ano, somente três apresentaram o percentual de exames compatíveis com HSIL acima do recomendado pelo Ministério da Saúde. Conclusão A maioria dos laboratórios prestadores de serviço para o SUS no estado de Minas Gerais apresentou indicadores de qualidade fora dos parâmetros recomendados pelo Ministério da Saúde.